Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress
Bezuclastinib showed significant clinical improvement in patients with Advanced Systemic Mastocytosis (AdvSM), with an updated objective response rate of 65% as per mIWG criteria and 81% as per PPR criteria. This indicates a rapid and profound response to the treatment in a majority of patients.